摘要
目的探讨氟哌噻吨美利曲辛联合舍曲林治疗脑卒中后抑郁(PSD)的临床疗效,为采取有效的临床预防措施、改善患者的预后提供依据。方法选择2012年1月至2015年1月东莞市南城医院门诊和住院治疗的PSD患者共100例,按随机数字表法分为观察组和对照组,各50例。对照组给予舍曲林治疗,观察组给予氟哌噻吨美利曲辛联合舍曲林治疗。比较两组患者治疗前后抑郁自评量表(SDS)评分、焦虑自评量表(SAS)评分及简明健康调查量表(SF-36)评分。结果治疗前,两组患者SDS评分和SAS评分比较差异均无统计学意义(P均>0.05);治疗后,观察组SDS评分和SAS评分较治疗前均显著降低,且低于对照组治疗后(P均<0.05)。治疗前,两组患者SF-36各维度评分比较差异无统计学意义(P均>0.05);治疗后,观察组SF-36各维度(除躯体疼痛外)评分显著增高,且高于对照组治疗后(P均<0.05);两组患者治疗后不良反应发生率比较无统计学差异(P>0.05)。结论氟哌噻吨美利曲辛联合舍曲林治疗PSD患者,可显著改善患者焦虑及抑郁症状,提高生活质量,其效果优于单纯舍曲林治疗。
Objective To investigate the clinical effect of Flupentixol/Melitracen combined with sertraline for treatment of post-stroke depression（PSD） to provide a basis for taking effective preventive measures and improving the prognosis of pa- tients. Methods A total of 100 patients with PSD treated in outpatient and inpatient department of Dongguan Hospital of Nancheng between January 2012 and January 2015 were selected. The patients were randomly divided into observation group and control group （ n=50 each） according to random number table method. The patients in control group received sertraline treatment, and the patients in observation group received Flupentixol/Melitracen plus sertraline treatment. Self- Rating Depression Scale （SDS） score, Self-Rating Anxiety Scale （SAS） score and Concise Health Examination Survey Scale （SF-36） score before and after treatment were compared between two groups. Results Before treatment, there were no sig- nificant differences in SDS and SAS scores between two groups （ all P 〉 0. 05 ）. After treatment, SDS and SAS scores in ob- servation group were significantly lower than those before treatment in this group and after treatment in control group （all P 〈 O. 05 ）. Before treatment, there were no significant differences in the scores of each dimension of SF-36 between two groups （ all P 〉 O. 05）. After treatment, the scores of each dimension of SF-36 （ except for body pain） in observation group were significantly higher than those before treatment in this group and after treatment in control group（ all P 〈 O. 05 ）. There was no significant difference in the incidence of adverse reactions after treatment between two groups（P 〉 O. 05 ）. Conclu- sions For the treatment of PSD, Flupentixol/Melitracen plus sertraline can significantly reduce patients＇ anxiety and de- pression symptoms and improve the quality of life, and its effect is better than that of sertraline alone.
出处
《中国临床研究》
CAS
2017年第4期444-446,450,共4页
Chinese Journal of Clinical Research
基金
广东省东莞市高等院校
科研机构和医疗卫生单位科技计划项目(2011105102027)
